SCHEMBL5020698

SCHEMBL5020698

CN(C)c1ccc(CCc2ccccc2C(=O)NO)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.52
HDAC6 Q9UBN7 3/20 0.52
ALDH1A1 P00352 5/20 0.51
ADRB2 P07550 1/20 0.51
HTT P42858 1/20 0.50
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
KDM4E B2RXH2 1/20 0.49
KDR P35968 1/20 0.47
MAPT P10636 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
HDAC4 P56524 1/20 0.43
NPC1 O15118 1/20 0.43
ALOX15 P16050 1/20 0.43
NFKB1 P19838 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
MCL1 Q07820 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL974386 0.83 ALDH1A1 (0.71) HDAC1HDAC6ALDH1A1ADRB2HTT
SCHEMBL5020667 0.79 HDAC6 (0.81) HDAC1HDAC6ALDH1A1HTTKDM4E
SCHEMBL5020695 0.74 HDAC6 (0.60) HDAC1HDAC6ALDH1A1SMN1; SMN2KDM4E
SCHEMBL11783350 0.74 ALDH1A1 (0.57) ALDH1A1ADRB2HTTLMNASMN1; SMN2
SCHEMBL8773450 0.72 GAA (0.55) HDAC1HDAC6ALDH1A1HTTLMNA
SCHEMBL7970930 0.72 ALDH1A1 (0.69) ALDH1A1ADRB2HTTLMNASMN1; SMN2
SCHEMBL11148178 0.72 HTT (0.50) HDAC1ALDH1A1ADRB2HTTLMNA
SCHEMBL11407984 0.72 ALDH1A1 (0.70) ALDH1A1ADRB2HTTLMNASMN1; SMN2
SCHEMBL5020697 0.71 HDAC1 (0.52) HDAC1HDAC6ALDH1A1HTTKDM4E
SCHEMBL22994602 0.70 ALDH1A1 (0.71) HDAC1ALDH1A1ADRB2HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796330-B2 Inhibitors of histone deacetylase and prodrugs thereof METHYLGENE INC. (CA) 2014-08-05 US disclosed
US-8796330-B2 Inhibitors of histone deacetylase and prodrugs thereof METHYLGENE INC. (CA) 2014-08-05 US disclosed
US-20140024608-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2014-01-23 US disclosed
US-20140024608-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2014-01-23 US disclosed
US-RE43343-E1 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-05-01 US disclosed
US-RE43343-E1 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-05-01 US disclosed
WO-2008074132-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2008-06-26 WO disclosed
US-20080146623-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2008-06-19 US disclosed
US-RE39850-E1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents METHYLGENE, INC. (CA) 2007-09-18 US disclosed
US-RE39850-E1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents METHYLGENE, INC. (CA) 2007-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146623-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF HDAC1, HDAC3, HDAC11 HDAC1 1/4885HDAC6 10/4885ALDH1A1 521/4885
US-20140024608-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF HDAC1, HDAC3, HDAC11 HDAC1 1/4885HDAC6 10/4885ALDH1A1 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.